Tinea Pedis
7
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
3
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Bausch HealthQUEBEC, Quebec, Canada
2 programs2
Luliconazole Cream 1%Phase 41 trial
Omeprazole 40 mgPhase 4
Active Trials
DermBiontMA - Boston
2 programs2
DBI-001 GelPhase 21 trial
Janthinobacterium lividumPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bausch HealthLuliconazole Cream 1%
Bausch + LombOmeprazole 40 mg
DermBiontDBI-001 Gel
DermBiontJanthinobacterium lividum
PfizerAN2718
GSKW0027
Clinical Trials (6)
Total enrollment: 220 patients across 6 trials
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Start: Dec 2015Est. completion: Apr 2016
Phase 4Completed
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Start: Feb 2015Est. completion: Apr 201520 patients
Phase 4Completed
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
Start: Sep 2022Est. completion: Dec 202324 patients
Phase 2Unknown
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Start: Feb 2019Est. completion: Apr 201912 patients
Phase 2Completed
Cumulative Irritation Test
Start: Oct 2008Est. completion: Nov 200844 patients
Phase 1Completed
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
Start: Jul 2007Est. completion: Aug 2008120 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 companies competing in this space